Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Fujifilm Diosynth Biotechnologies (FDB) is a globally recognized Contract Development and Manufacturing Organization (CDMO) specializing in the development and manufacturing of biologics, vaccines, gene therapies, and other advanced biopharmaceuticals. With state-of-the-art facilities and decades of experience, FDB partners with pharmaceutical and biotech companies worldwide to bring innovative medicines to patients. Their services span from cell line development, process and analytical development, to clinical and commercial cGMP manufacturing, leveraging expertise in microbial, mammalian, and viral-based production systems.
Large-scale contract development and manufacturing (CDMO) of biologics, including monoclonal antibodies via cell culture, microbial fermentation products, and gene therapies. Serves as a strategic site for end-to-end biopharmaceutical production and innovation.
State-of-the-art, highly automated facility designed for sustainability and efficiency. Set to be North America’s largest end-to-end biopharmaceutical manufacturing facility, featuring multiple 20,000L bioreactors.
The work culture at Fujifilm Diosynth Biotechnologies, including its Holly Springs site, emphasizes innovation, quality, patient focus, and collaboration. Employees often highlight a commitment to scientific excellence, continuous improvement, and a 'Partners for Life' philosophy with clients. There's a strong sense of purpose tied to advancing human health.
The Holly Springs facility is a cornerstone of Fujifilm's multi-billion dollar investment in expanding its Bio CDMO business. It significantly enhances FDB's capacity to meet the growing global demand for advanced therapies and vaccines, positioning it as a key player in the biopharmaceutical supply chain.
Fujifilm Diosynth Biotechnologies maintains a robust global presence with strategically located cGMP manufacturing and development facilities in the United States (North Carolina, Texas, California), the United Kingdom (Billingham), and Denmark (Hillerød). This international network enables the company to provide comprehensive, end-to-end services—from cell line and process development through to clinical and commercial scale manufacturing of biologics, vaccines, and advanced therapies (gene and cell therapies)—to a diverse global client base in the pharmaceutical and biotechnology industries.
5501 FUJIFILM Way
Holly Springs
North Carolina
USA
Address: Belasis Avenue, Billingham, TS23 1LH, UK
Serves as a major European hub for microbial-based biomanufacturing, viral product development, and cell and gene therapy services, supporting clients globally.
Address: Biotek Allé 1, DK-3400 Hillerød, Denmark
Strengthens FDB's European presence for large-scale commercial manufacturing of mammalian cell culture-derived biologics, supporting global supply chains for advanced therapies.
Address: 3939 Biomedical Way, College Station, TX 77845, USA
A critical U.S. site for the development and manufacturing of gene therapies and viral products, catering to the rapidly growing advanced therapies market and national preparedness needs.
Address: Multiple locations within RTP, e.g., 6051 George Watts Hill Dr, Research Triangle Park, NC 27709, USA
Serves as a core R&D and manufacturing center in North America, leveraging the rich biotech ecosystem of the Research Triangle region to support global clients.
Address: 2345 W. Wuthrich Ave, Thousand Oaks, CA 91320, USA
Provides critical downstream drug product capabilities on the U.S. West Coast, complementing FDB's drug substance manufacturing network.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, FUJIFILM Diosynth Biotechnologies' leadership includes:
FUJIFILM Diosynth Biotechnologies has been backed by several prominent investors over the years, including:
In the past 12 months, Fujifilm Diosynth Biotechnologies has continued to strengthen its leadership team with key appointments, such as the Chief Quality & Compliance Officer, reflecting its commitment to operational excellence and growth. Other executive roles have evolved to support the company's expanding global operations and strategic initiatives. No major C-level departures have been publicly announced.
Discover the tools FUJIFILM Diosynth Biotechnologies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Fujifilm Diosynth Biotechnologies commonly uses the `first.last@fujifilmdiosynth.com` email format for its employees. While this is a prevalent pattern, other formats like `firstinitiallast@fujifilmdiosynth.com` may also be in use, and variations can exist depending on the region or legacy systems from acquired entities.
first.last@fujifilmdiosynth.com
Format
jane.doe@fujifilmdiosynth.com
Example
80%
Success rate
fujifilmdiosynth.com • May 15, 2024
Fujifilm Diosynth Biotechnologies and Selecta Biosciences are collaborating to advance Selecta's ImmTOR™ platform for gene therapy applications. FDB will provide CDMO services for process development and cGMP manufacturing of ImmTOR, aiming to improve the safety and efficacy of gene therapies....more
fujifilmdiosynth.com • May 1, 2024
Fujifilm Diosynth Biotechnologies and LEXEO Therapeutics have entered a strategic manufacturing collaboration. FDB will provide process development and cGMP manufacturing services for LEXEO's AAV-mediated gene therapy candidates, leveraging FDB's expertise and capacity in viral vector production....more
fujifilmdiosynth.com • March 26, 2024
Fujifilm Diosynth Biotechnologies has commenced its first cell culture expansion at its new, large-scale facility in Holly Springs, NC. This milestone marks a significant step towards the facility's full operational capability, which will feature 8 x 20,000L bioreactors for monoclonal antibody production....more
fujifilmdiosynth.com • February 27, 2024
Fujifilm Diosynth Biotechnologies is expanding its capabilities by adding a new KUBio® box for aseptic fill-finish services at its Thousand Oaks, California facility. This expansion will provide flexible, high-quality drug product manufacturing for late-phase and commercial biologics....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including FUJIFILM Diosynth Biotechnologies, are just a search away.